Cosmos Health (NASDAQ:COSM) reported further progress under its share repurchase program of up to $5 million.
The company recently bought an additional 230,000 shares at an average price of about $0.2539, bringing total repurchases to 3,870,000 shares for approximately $758,000, with the program running through December 31, 2026.
Loading…
Loading translation…
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Additional 230,000 shares repurchased at an average price of about $0.2539
- Total 3,870,000 shares repurchased to date for approximately $758,000
- Ongoing buyback authorized up to a total of $5 million
- Program runs through December 31, 2026, allowing continued repurchases
- Management signals confidence in business trajectory via continued buybacks
Negative
- Approximately $758,000 of cash spent on share repurchases to date
-4.89%
News Effect
+23.7%
Peak Tracked
-24.7%
Trough Tracked
-$861K
Valuation Impact
$16.75M
Market Cap
0.7x
Rel. Volume
On the day this news was published, COSM declined 4.89%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +23.7% during that session.
Argus tracked a trough of -24.7% from its starting point during tracking.
Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility.
This price movement removed approximately $861K from the company’s valuation, bringing the market cap to $16.75M at that time.
Data tracked by StockTitan Argus on the day of publication.
New shares repurchased
230,000 shares
Latest open market buyback tranche
Average repurchase price
$0.2539 per share
Price paid for latest 230,000-share repurchase
Total shares repurchased
3,870,000 shares
Cumulative buybacks under current program
Total repurchase cost
$758,000
Cumulative spend under buyback program to date
Buyback authorization
$5 million
Maximum size of current share repurchase program
Program expiry
December 31, 2026
Scheduled end date of buyback program
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 06 | Positive | +13.8% |
Disclosed additional 220,000-share buyback, lifting total repurchases to 3.64M shares. |
|
| Jul 02 | Positive | +17.6% |
Reported 770,000-share repurchase, taking cumulative buybacks to 3.42M shares. |
|
| Jul 01 | Positive | +9.2% |
Announced initial 2.65M-share repurchase for $500,000 under new program. |
|
| Jun 30 | Positive | +5.5% |
Authorized share repurchase program of up to $5M running through December 31, 2026. |
Recent Cosmos Health buyback announcements have coincided with consistently positive next‑day price reactions.
+11.5%
Average Historical Move
buybacks
Across four prior buyback headlines in this window, Cosmos Health moved about 11.53% on average, all positively. This update continues the same repurchase theme, aligning in substance with that earlier series of announcements.
Same‑tag history shows a clear progression from initial authorization of a $5M buyback to successive disclosures of larger cumulative repurchases, indicating stepwise execution of the capital return plan.
5.62% of float
0%
15%
30%+
low
as of 2026-06-15
Days to cover: 1
Short interest appears relatively low, suggesting limited scope for a short squeeze and implying trading is more likely to track fundamentals and news flow than forced covering.
$200,000,000
registered capacity
An effective S-3/A shelf covering up to $200,000,000 in securities provides flexibility for future capital raises, which could introduce dilution risk if used, even as the company executes concurrent share repurchases.
sec rules 10b5-1
regulatory
“in accordance with SEC Rules 10b5-1 and 10b-18 and other applicable”
SEC Rule 10b5-1 allows company insiders to set up a written, prearranged trading plan that specifies when and how many shares to buy or sell, so trades occur automatically at later dates regardless of what the insider knows at the time. For investors, these plans matter because they provide a clearer signal that certain insider trades were pre-planned and not based on undisclosed information, reducing uncertainty about motive—think of it like a standing instruction to a bank that separates routine payments from one-off decisions.
10b-18
regulatory
“in accordance with SEC Rules 10b5-1 and 10b-18 and other applicable”
SEC Rule 10b-18 is a regulatory safe harbor that sets precise limits on how a company may repurchase its own shares on the open market—specifying acceptable timing, maximum daily volume, price conditions and the trading venues—so those buybacks are less likely to be treated as illegal market manipulation. For investors, it acts like traffic rules for buybacks: when a company follows them, repurchases are more predictable and reduce legal and reputational risk, making the likely impact on share supply and price easier to assess.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, July 07, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 230,000 shares of its common stock in the open market at an average price of approximately
The Company has now repurchased a total of 3,870,000 shares for approximately
The Company intends to continue making open market repurchases, subject to market conditions, under the program, which expires on December 31, 2026, and may be renewed at the Company’s sole discretion.
Greg Siokas, CEO of Cosmos Health, stated: “We are continuing to repurchase our shares with discipline and conviction, reflecting our belief that the market continues to undervalue the strength of our platform and the trajectory of our business.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
FAQ
Why is Cosmos Health continuing open market repurchases of COSM stock?
Cosmos Health’s CEO links continued repurchases to confidence in the company’s platform and trajectory. According to Cosmos Health, management is buying back shares with “discipline and conviction,” reflecting a belief that the market undervalues the business’s strength and prospects.
